Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome

FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S.FDA expressed openness to an alternative ...

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome

FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S. FDA expressed openness to an alternative study design for Phase 3 that would likely not include a ...

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Closes Private Placement Financing of Up to $104.5 Million – Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the ...

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Closes Private Placement Financing of Up to $104.5 Million - Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe - Advances Proposed Expedited Regulatory ...
InvestorsHub on MSN

Quoin advances QRX003 development after positive FDA meeting on Netherton syndrome

Quoin Pharmaceuticals (NASDAQ:QNRX) said it received encouraging regulatory feedback from the U.S. Food and Drug ...

DWP paying out for 'ridiculous' PIP condition - full list of 178 that qualify

The DWP has confirmed 178 conditions eligible for Personal Independence Payment ...

Tuberculosis Therapeutics Market Size is Expected to be Valued at USD 3.95 Billion by 2035 Owing to the Consistent Need for Tuberculosis Pharmaceuticals Globally | SNS Insider

U.S. Tuberculosis Therapeutics Market was valued at USD 0.63 billion in 2025 and is expected to reach USD 1.04 billion by 2035 owing to robust public health fundingAustin, March 24, 2026 (GLOBE ...